亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5239: Probing the cancer epigenome: empowering target validation by open innovation

作者
Ingo Volker Hartung,C.H. Arrowsmith,Volker Badock,Naomi N. Barak,Markus Berger,Peter J. Brown,Clara D. Christ,Erik Eggert,Ursula Egner,Oleg Fedorov,Amaury E. Fernández‐Montalván,Mátyás Gorjánácz,Andrea Haegebarth,Bernard Haendler,Roman Christian Hillig,Simon H. Holton,K. Huber,Seong Joo Koo,Antonius ter Laak,Susanne Müller
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 5239-5239
标识
DOI:10.1158/1538-7445.am2017-5239
摘要

Abstract Low reproducibility of published target validation studies as well as the frequent failure of genetic knock-down effects to phenocopy those of small molecule inhibitors have been recognized as road blocks for cancer drug discovery. Academic and industrial institutions have started to address these issues by providing access to high quality small molecular probes for novel targets of interest. Here we discuss probe discovery challenges and quality criteria based on the generation of three novel inhibitors for epigenetic targets. ATAD2 (ATPase family AAA-domain containing protein 2) is an epigenetic regulator that binds to chromatin through its bromodomain (BD). ATAD2 has been proposed to act as a co-factor for oncogenic transcription factors such as ERα and Myc. A more thorough validation of ATAD2 as a therapeutic target has been hampered by the lack of appropriate ATAD2 inhibitors. Here we disclose a structurally unprecedented series of ATAD2 BD inhibitors identified from a DNA-encoded library screen. Optimization delivered BAY-850, a highly potent and exceptionally selective ATAD2 BD inhibitor, which fully recapitulates effects seen by genetic mutagenesis studies in a cellular assay. The three BD and PHD-finger (BRPF) family members are found in histone acetyltransferase complexes. Whereas bromodomain inhibitors with dual activity against BRPF1 and 2 have been described before, we now disclose BAY-299, the first nanomolar inhibitor of the BRPF2 BD with high selectivity against its paralogs. Isoform selectivity was confirmed in cellular protein-protein interaction assays and rationalized based on X-Ray structures. BAY-598, a highly selective, cellularly active and orally bioavailable inhibitor of the protein lysine methyl transferase SMYD2, had been disclosed previously (Stresemann et al., AACR 2015). Development of BAY-598 allowed the identification of new methylation targets of SMYD2 as well as a proposed role of SMYD2 in pancreatic cancer. These results support further development of small molecule inhibitors as research tools to probe the functional role of novel epigenetic targets and underscore the power of open innovation for advancing our understanding of cancer target biology. Citation Format: Ingo V. Hartung, Cheryl Arrowsmith, Volker Badock, Naomi Barak, Markus Berger, Peter J. Brown, Clara D. Christ, Erik Eggert, Ursula Egner, Oleg Fedorov, Amaury E. Fernandez-Montalvan, Matyas Gorjanacz, Andrea Haegebarth, Bernard Haendler, Roman C. Hillig, Simon H. Holton, Kilian V. Huber, Seong J. Koo, Antonius ter Laak, Susanne Mueller, Anke Mueller-Fahrnow, Cora Scholten, Stephan Siegel, Timo Stellfeld, Detlef Stoeckigt, Carlo Stresemann, Masoud Vedadi, Joerg Weiske, Hilmar Weinmann. Probing the cancer epigenome: empowering target validation by open innovation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5239. doi:10.1158/1538-7445.AM2017-5239

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
summer完成签到,获得积分10
2秒前
h11的应助被渡增越采纳,获得10
3秒前
4秒前
染8完成签到 ,获得积分10
4秒前
TBI发布了新的文献求助10
5秒前
VV2001完成签到,获得积分10
5秒前
7秒前
ddwdwdwdddw发布了新的文献求助10
9秒前
fuzhenwei完成签到 ,获得积分10
11秒前
13秒前
生动火龙果完成签到 ,获得积分10
14秒前
跳跃奇异果完成签到 ,获得积分10
14秒前
h11的应助被jiang采纳,获得10
16秒前
研猫发布了新的文献求助10
18秒前
fuzhenwei关注了科研通微信公众号
19秒前
平淡水之完成签到,获得积分10
21秒前
24秒前
ddwdwdwdddw完成签到,获得积分10
24秒前
Lucas的应助被科研通管家采纳,获得10
25秒前
ding的应助被科研通管家采纳,获得10
25秒前
Lucas的应助被科研通管家采纳,获得10
25秒前
ccczzz完成签到,获得积分10
26秒前
桴子完成签到,获得积分10
26秒前
27秒前
28秒前
烟花的应助被henryhc_采纳,获得10
29秒前
Jasper的应助被dongshao2027采纳,获得10
29秒前
30秒前
binwu完成签到,获得积分10
31秒前
breeze发布了新的文献求助10
31秒前
32秒前
大个的应助被苏折采纳,获得50
33秒前
34秒前
binwu发布了新的文献求助10
35秒前
无极微光的应助被木子媚媚采纳,获得20
37秒前
研猫发布了新的文献求助10
37秒前
breeze完成签到,获得积分10
39秒前
39秒前
39秒前
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554333
关于积分的说明 21718908
捐赠科研通 7748056
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551841
邀请新用户注册赠送积分活动 2471242